Equity (Tables)

12 Months Ended

Dec. 31, 2024

Share Capital [Member]

Disclosure of classes of share capital [line items]

Schedule of Classes of Share Capital

	2024		2023		2022		2024		2023		2022
	Number ‘000		Number ‘000		Number ‘000		A$’000		A$’000		A$’000
Balance at January 1,		323,727		316,343		285,073		446,268		370,972		170,840
Shares issued through the exercise of share options and warrants1		525		3,879		8,543		8,080		42,572		32,948
Contributions of equity2		-		-		22,727		-		-		175,000
Shares issued for Dedicaid3		-		207		-		-		1,829		-
Shares issued for Lightpoint4		-		3,298		-		-		30,895		-
Shares issued for IsoTherapeutics5		718		-		-		8,912		-		-
Shares issued for ARTMS6		5,675		-		-		71,610		-		-
Shares issued for QSAM7		4,080		-		-		61,906		-		-
Transaction costs arising on new share issues		-		-		-		-		-		(7,816	)
Balance at December 31,		334,725		323,727		316,343		596,776		446,268		370,972

1. Options exercised during the year through the employee Equity Incentive Plan resulted in 525,000 (2023: 3,879,000, 2022: 8,543,000) shares being issued of total value of $8,080,000 (2023: $42,572,000, 2022: $32,948,000).

2. On January 27,2022, the Group completed a $175,000,000 institutional placement of 22,727,000 new, fully paid ordinary shares at a price of $7.70 per share. As part of this placement, the Group also incurred $7,816,000 of associated transaction costs.

3. On April 27, 2023, the Group completed the acquisition of Dedicaid GmbH. The consideration for the acquisition comprised 207,000 in Telix shares at a 10-day volume weighted average price of shares on the execution date of $8.73 per share.

4. On November 1, 2023, the Group completed the acquisition of Lightpoint through the issue of 3,298,000 fully paid ordinary Telix shares at $9.3659 per share.

5. On April 9, 2024, the Group completed the acquisition of IsoTherapeutics. The consideration included the issue of 717,587 fully paid ordinary Telix shares at $12.42 per share.

6. On April 11, 2024, the Group completed the acquisition of ARTMS. The consideration included the issue of 5,674,365 fully paid ordinary Telix shares at $12.62 per share.

7. On May 3, 2024, the Group completed the acquisition of QSAM. The purchase price included the issue of 3,671,120 fully paid ordinary Telix shares at $14.80 per share and a further 409,026 fully paid ordinary Telix shares at $18.05 per share.

Share Capital Reserve [Member]

Disclosure of classes of share capital [line items]

Schedule of Classes of Share Capital

	2024			2023			2022			2024			2023			2022
	Number ’000			Number ’000			Number ‘000				A$’000			A$’000			A$’000
Balance at January 1	-			-			-				(62,829	)		(26,909	)		-
Treasury shares acquired		525			3,877			4,054			(7,081	)		(35,920	)		(26,909	)
Issue of convertible bonds		-			-			-			97,900			-			-
Transaction costs arising on convertible bonds issue		-			-			-			(2,245	)		-			-
Shares allocated to employees		(525	)		(3,877	)		(4,054	)		-			-			-
Balance at December 31		-			-			-			25,745			(62,829	)		(26,909	)

Other Reserves [Member]

Disclosure of classes of share capital [line items]

Schedule of Classes of Share Capital

	Foreign currency translation reserve			Share-based payments reserve			Financial assets at FVOCI reserve			Total
		A$‘000			A$’000			A$’000			A$’000
Balance as at January 1, 2024		(5,414	)		35,446			(895	)		29,137
Other comprehensive income		47,684			-			(4,986	)		42,698
Total comprehensive income		47,684			-			(4,986	)		42,698
Share-based payments to employees		-			19,660			-			19,660
Share-based payments associated with acquisitions		-			67,943			-			67,943
Transfer on exercise of options		-			(784	)		-			(784	)
		-			86,819			-			86,819
Balance as at December 31, 2024		42,270			122,265			(5,881	)		158,654

	Foreign currency translation reserve			Share-based payments reserve			Financial assets at FVOCI reserve			Total
		A$‘000			A$’000			A$’000			A$’000
Balance as at January 1, 2023		(562	)		9,321			-			8,759
Other comprehensive income		(4,852	)		-			(895	)		(5,747	)
Total comprehensive loss		(4,852	)		-			(895	)		(5,747	)
Share-based payments to employees		-			8,786			-			8,786
Share-based payments associated with acquisitions		-			21,278			-			21,278
Transfer on exercise of options		-			(3,939	)		-			(3,939	)
		-			26,125			-			26,125
Balance as at December 31, 2023		(5,414	)		35,446			(895	)		29,137

	Foreign currency translation reserve			Share-based payments reserve			Financial assets at FVOCI reserve		Total
		A$‘000			A$’000			A$’000		A$’000
Balance as at January 1, 2022		(1,153	)		5,942			-		4,789
Other comprehensive income		591			-			-		591
Total comprehensive income/(loss)		591			-			-		591
Share-based payments to employees		-			8,114			-		8,114
Transfer on exercise of options		-			(4,735	)		-		(4,735	)
		-			3,379			-		3,379
Balance as at December 31, 2022		(562	)		9,321			-		8,759

Share-based payment reserve [Member]

Disclosure of classes of share capital [line items]

Schedule of Classes of Share Capital

	2024			2023			2022
	Number ’000			Number ’000			Number ‘000
Balance at January 1	14,601			11,736			17,148
EIP options issued		9,877			6,689			4,436
Performance Rights issued1		4,284			2,524			-
Options exercised		(619	)		(4,524	)		(8,843	)
Options lapsed		(2,621	)		(1,824	)		(1,005	)
Balance at December 31		25,522			14,601			11,736

1. Relates to the acquisition of QSAM in the current period and Lightpoint in the prior year.

Financial Assets at FVOCI Reserve [Member]

Disclosure of classes of share capital [line items]

Schedule of Classes of Share Capital

The table below shows how the FVOCI reserve relates to equity securities:

	2024			2023			2022
	A$’000			A$’000			A$’000
Balance at January 1		(895	)		-			-
Revaluation - gross		(4,986	)		(895	)		-
Deferred tax		-			-			-
Balance at December 31		(5,881	)		(895	)		-